Robert Royer lost his year-long battle with Merkel cell carcinoma on April 17, 2019, in the setting of also having chronic lymphocytic leukemia (CLL). Mr. Royer was a passionate civic leader, serving as deputy mayor for the city of Seattle from 1978 to 1983. To read the Seattle Times obituary for Mr. Royer please click here. For an extended historical article on Mr. Royer’s civil service and legacy, please click here.
Mr. Royer left a profound impact on Drs. Paul Nghiem, Kelly Paulson, and our extended MCC clinical and research teams. He was grateful that his beloved Seattle has become a leading center for research and clinical care of MCC. After working with the Seattle MCC team, Bob was excited about the research that is rapidly helping patients, as well as the training of many young, bright scientists on the team.
Bob was dismayed by how aggressive MCC can be, particularly in the setting of chronic lymphocytic leukemia (CLL) which leads to immune suppression. Indeed, MCC is nearly 50 times more likely to arise in patients with CLL, and this cancer is particularly difficult to treat when CLL is also present. Excitingly, newly available approaches to treat CLL may also directly help treat MCC. In addition, treating the CLL may help return immune function to a more normal status, allowing the immune system to fight the MCC more effectively.
For all of these reasons, in Bob’s honor, we have created a fund to study and help patients who have both MCC & CLL.
If you would like to make a donation to contribute to this goal, in honor of Mr. Royer, please click here. When you reach the question “Is this a gift in honor or memory of someone?”, click ‘in honor’ and write in “Robert Royer”.Make a Donation
The authoritative source on Merkel cell carcinoma.
May 20, 2020
- What is a Merkel cell?
- What is Merkel cell carcinoma?
- Symptoms & appearance of Merkel cell carcinoma
- Causes of Merkel cell carcinoma
- Surgical excision
- Mohs micrographic surgery
- Radiation therapy
- Complementary & alternative therapies
- Clinical trials
- Adjuvant Avelumab in Merkel Cell Carcinoma Trial